The change separates two propositions that USTR's initiation notice placed in one narrative. One is what the enacted German rules extract from covered medicines. The other is what part of that effect burdens or restricts U.S. commerce. The first requires a coverage and incidence model. The second requires a defensible causal bridge to U.S. commerce. Removing the automatic ratchet changes the evidence for both questions without answering either one.
The ratchet disappeared, the savings target did not
The Office of the U.S. Trade Representative, Section 301 initiation notice, 91 FR 38072, June 24, 2026 described a draft German measure that would begin with a 3.5 percent rebate for the first half of 2027 and then recalculate the rate from the difference between actual and target pharmaceutical expenditures. Target expenditures would have been derived from prior spending and adjusted by the average change in members' contributory income. USTR cited one estimate that the dynamic rate could approach 20 percent by 2030. That projected escalation gave the notice a simple narrative. German underpayment was not merely persistent. It was about to become more severe through an automatic formula.
The enacted text breaks that narrative. German Federal Ministry of Justice, Social Code Book V, Section 130a now provides an additional 8.5 percent rebate rather than an annual automatic recalculation. The German Federal Ministry of Health, final-law summary, July 10, 2026 says the dynamic manufacturer rebate was replaced with a statutory increase in the static rebate to 15.5 percent. The official reason was twofold. Germany wanted an immediate contribution to expenditure restraint and a more predictable framework for product launches, investment, and location decisions.
Predictability is not the same as relief. The committee report states that the 8.5 percent addition is expected to deliver approximately the same aggregate savings over 2027 through 2030 as the dynamic rebate. It also explains that the discarded formula would have reacted after an earlier deficit emerged, while the fixed rate begins producing a substantial effect in 2027. The final law therefore trades annual recalculation for a known rate with earlier fiscal effect.
The fixed rebate is designed as a continuing measure. The committee report says its future necessity should be revisited if broader reforms or unexpected fiscal room change the conditions. Section 130a also retains regulatory authority to reduce or remove rebates when economic conditions no longer justify them. Those qualifications matter. The rate has no annual automatic recalculation, but it is not beyond later legal adjustment.
The 15.5 percent headline is not product-level incidence
The new headline creates a second risk of overstatement. Fifteen and one-half percent is a statutory reference point, not a complete estimate of the net revenue effect on every medicine sold in Germany.
The 8.5 percent addition operates through Section 130a and is subject to coverage rules, exclusions, negotiated replacements, and product-specific interactions elsewhere in the reimbursement system. It can be displaced only by a Section 130b reimbursement agreement concluded on or after July 30, 2026, if that agreement expressly provides for displacement. Biosimilars and their biological reference products, along with the other categories enumerated in Section 130a(1b), are excluded from the additional rebate. From January 1, 2027, vaccines with patent or data protection are subject to a separate 9 percent additional rebate and to the price-increase rebate in Section 130a(3f) through December 31, 2030.
The Act also changes the price-volume rules in Section 130b. A Section 130b reimbursement agreement must address volume. If the agreement contains no negotiated price-volume rule, the statutory fallback adjusts the reimbursement amount annually, first from the fourth year after the active ingredient was first marketed.
The clinical-research exemption follows a different clock. A manufacturer of a medicine with a new active ingredient first marketed on or after January 1, 2027 may apply for the Section 130a exemption. BfArM must grant it when at least 5 percent of the participants in the relevant manufacturer-conducted or manufacturer-commissioned clinical trials were enrolled at German sites. The exemption takes effect when BfArM gives notice, no earlier than first marketing, and expires three years later unless renewed upon continued satisfaction of the condition.
These details do not make the headline irrelevant. They determine the denominator USTR needs. A sector-wide statutory rate can support an estimate of gross savings. It cannot by itself establish which U.S. firms, products, exports, services, or investments bear the alleged burden after exclusions and negotiated terms. Counsel preparing a hearing submission should separate the statutory headline from the product population to which it actually applies.
What USTR must now prove
The final law leaves USTR with two proof questions. One measures the German measure. The other measures the alleged U.S. burden.
The obsolete part is the variable-rate projection. USTR's initiation notice described a mechanism that Germany did not enact. A later Section 304 determination could not reasonably treat the projected path toward 20 percent as current law without addressing the superseding statute. USTR would need to explain how the enacted fixed rebate changes its analysis.
The second record is the asserted economic burden. USTR opened the investigation to test whether Germany's pricing practices are unreasonable or discriminatory and burden or restrict U.S. commerce. Its theory links lower German prices to lower manufacturer revenue, lower research investment, and a disproportionate U.S. share of global innovation costs. Replacing the formula does not answer that chain. The Bundestag's savings comparison may show that the enacted measure preserves much of the projected German fiscal effect. It does not show what portion falls on U.S. commerce.
One mechanism described in the notice changed materially. The broader allegation of persistent underpayment remains for USTR to prove against the enacted law. The earlier Traverse Analysis on the causation problem in Germany's drug-pricing case explains the weaknesses in the original causal chain. The final-law record now requires USTR to measure the German incidence before it can test that chain.
The local trial condition complicates the neutrality defense
Germany's basic rebate is facially neutral by domicile. A German, U.S., French, or Swiss manufacturer enters the same statutory framework when a covered medicine is reimbursed through the system. That fact weakens a simple nationality-discrimination theory.
The final exemption introduces a different question. Eligibility can depend on whether at least 5 percent of clinical-trial participants were enrolled at sites in Germany. The committee removed a separate German production-location criterion after identifying operational difficulty and the need to consider European and trade-law constraints. It retained the trial-site condition.
That condition should not be mislabeled as a finding of nationality discrimination. It does not turn on corporate nationality. A foreign company can qualify by conducting sufficient trial activity in Germany, while a German company can fail if it does not. The condition is better understood as a local-performance incentive inside a domicile-neutral rate.
For Section 301, that is still relevant. The statute permits USTR to examine practices it considers unreasonable even when they are not discriminatory or inconsistent with U.S. international legal rights. The local condition therefore does not rescue a weak discrimination theory, but it gives the record a concrete feature beyond the general price level. Trade counsel should test who can qualify, what conduct changes eligibility, and whether the incentive affects U.S. clinical services or investment. The answer must come from evidence, not from the label attached to the exemption.
The record changes the contest, not the legal standard
USTR's notice asked whether Germany's practices are unreasonable or discriminatory, whether they burden or restrict U.S. commerce, and what action, if any, should follow. Those remain open questions. The final law does not eliminate the independent unreasonable-practices route in 19 U.S.C. 2411. A practice need not violate an international legal right to fall within that category.
Any affirmative determination would still need to address the final fixed rate, product coverage, exclusions, exemptions, negotiated replacements, and the connection between German payment rules and a burden on U.S. commerce. It would also need to distinguish price comparison from causation. A gap between U.S. and German prices does not by itself establish how much of that difference the German rebate caused or how a revenue change affects research spending.
The U.S. Court of Appeals for the Federal Circuit, HMTX Industries LLC v. United States, No. 23-1891 held that the challenged USTR-made List 3 and List 4A tariff modifications were agency actions reviewable under the APA. Because those tariff lists were issued through notice-and-comment rulemaking, the court also required adequate treatment of significant comments. HMTX does not establish that every Section 301 determination or remedy carries identical procedural duties, but it makes the statutory explanation and treatment of material record objections consequential when USTR proceeds through agency rulemaking.
The Section 304 record needs two economic models
One model should measure Germany's policy. The other should measure the alleged U.S. burden. Combining them would hide the weakest links.
The German-policy model begins with the final Section 130a population. It should identify covered products, excluded categories, the timing of the 8.5 percent addition, qualifying clinical-trial exemptions, and Section 130b agreements that expressly replace the rebate. It should then distinguish gross statutory savings from net manufacturer incidence. The Bundestag's four-year aggregate estimate is evidence of Germany's fiscal objective, not a ready-made measure of U.S. commercial harm.
The U.S.-burden model begins where the German model ends. It needs a defensible account of which affected revenue belongs to U.S. commerce, how the relevant firms allocate research budgets, whether changes in German returns alter those budgets, and what part of any change is borne in the United States. Sector-level evidence may be sufficient if it is rigorous. Product-level or firm-level evidence could make the causal chain easier to test. The statute does not prescribe the unit of proof, but the agency must connect its chosen unit to the burden it finds.
This separation prevents two common shortcuts. A large German savings number is not automatically a U.S. burden number. A high U.S.-to-German price ratio is not automatically evidence that the rebate caused the difference. Each may support an inference. Neither completes the chain without assumptions that USTR identifies and defends.
The practical deliverable is a bridge table rather than one headline figure.
Record question
Current evidence
Missing proof
Final German measure
Fixed additional 8.5 percent from January 1, 2027, subject to statutory exclusions and relief
Covered product population and net incidence
German fiscal effect
Roughly comparable aggregate savings for 2027 through 2030
Implementation and realized savings
U.S. commercial nexus
USTR's revenue and R&D cost-shifting theory
Revenue allocation, research-budget response, and U.S. share
Customs consequence
No Section 304 action or product annex
Covered HTS lines, rate, origin instructions, and effective date
For each covered product group, counsel should map the statutory rate, exception status, negotiated replacement, estimated German revenue effect, U.S. commercial nexus, and evidence connecting that effect to research or other commerce. Missing cells are not proof against the investigation. They show where the current record remains inferential.
The hearing should follow the enacted text
The September 22 hearing is the first scheduled public forum after the law changed. Questions that still assume the dynamic formula will waste that opportunity.
The first line of inquiry should establish the current legal baseline. Witnesses should identify which medicines receive the 8.5 percent addition, when it begins, which categories are excluded, and how an express Section 130b agreement can replace it. The second line should isolate the clinical-trial exemption. The record needs to show how the 5 percent threshold is calculated, how long relief lasts, and whether the condition changes investment or trial-location decisions.
Economic questions should then move from German savings to U.S. commerce in stages. A witness relying on the Bundestag aggregate should explain how the estimate translates into manufacturer incidence. A witness asserting reduced research should identify the decision rule or evidence connecting revenue and research budgets. A witness invoking U.S. prices should explain why the comparison measures German conduct rather than differences in the U.S. payment system.
Agency counsel also needs a clean timeline. The Traverse Policy Signal, USTR Section 301 investigation of Germany drug pricing, 91 FR 38072 remains the proceeding anchor, but the hearing file should place the enacted statute and final German legislative report after it. That makes the change in premise visible to anyone later reviewing a Section 304 determination.
For corporate counsel, the same timeline belongs in the internal matter file. The original notice, final law, hearing testimony, rebuttal submissions, and any negotiated U.S.-Germany arrangement should remain separate records. Replacing the original notice with a current summary would erase the change the agency now has to address.
What importers should do before USTR names a tariff
The enacted German law changes the merits record. It does not create a U.S. customs charge. USTR has not issued a Section 304 determination, proposed action, product annex, tariff rate, country-of-origin rule, or effective date for this investigation. Importers therefore have no new Section 301 duty to accrue from the Germany pharmaceutical docket.
Customs teams should wait for an action with an annex, rate, timing, and origin treatment before changing duty models. The earlier Traverse Analysis on possible off-sector tariffs in the Germany pharma case explains why any future remedy could extend beyond medicines. For now, trade counsel needs a hearing file and importers need a watch file, not an entry-summary calculation.
What would change the calculus in the record
Evidence can change the burden assessment without changing either statute. Credible product-level, firm-level, or sector-level work connecting the final rebate's incidence to U.S. commerce would strengthen USTR's case. Evidence showing that the savings are absorbed without the asserted U.S. effect would weaken it. The rate alone cannot answer that dispute.
An Office of the Law Revision Counsel, 19 U.S.C. 2414, USTR determination would show whether USTR actually uses the fixed-rebate record and how it connects German savings to the United States. A proposed action would answer the separate customs questions about product scope, rate, origin, and timing. Until then, the incidence and burden analyses should remain separate.
Bottom line
Germany replaced the variable formula with a fixed 8.5 percent addition. The change removes the projected path toward 20 percent as a current-law premise, while the Bundestag still projects roughly comparable aggregate savings through 2030. That leaves USTR with a different record, not a proved burden.
For September 22, pharma counsel should map final Section 130a coverage, exclusions, exemptions, and replacement agreements before translating German savings into U.S. commerce. Customs teams should not accrue a Germany Section 301 duty unless USTR later issues an action with a product annex, rate, origin instructions, and effective date.
Caveats
The German statutory headline combines the existing 7 percent rebate and the new 8.5 percent addition. It is not a quantified estimate of net incidence after exclusions, exemptions, price-volume rules, and express Section 130b replacements.
The Bundestag committee report describes approximately equal aggregate savings for 2027 through 2030. That projection is Germany's legislative estimate and remains subject to implementation, market behavior, and later legal adjustment.
USTR has not issued a Section 304 determination. Litigation outcomes also remain uncertain. HMTX confirms APA reviewability for the USTR-made tariff modifications before the court, but it did not decide whether this drug-pricing theory satisfies Section 301 or establish the precise review framework for a future Germany Section 304 determination.
As of August 13, 2026, no Section 301 product list, rate, origin rule, or effective date has been announced for the Germany pharmaceutical investigation.
From reading to review
Run the numbers on your lane.
The duty calculator runs the current stack for any HTS code and origin. A free account opens full tool output, AD/CVD detail, Chapter 98 processing, and available exports.